This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Acute myelogenous leukemia (AML); myelodysplastic syndrome (MDS)	IL-1 receptor accessory protein (IL-1RAP)	<p><i>In vitro</i> and human studies suggest IL-1RAP could be a prognostic marker of AML and MDS. In hematopoietic stem cells and granulocyte-monocyte progenitor cells from patients with AML and MDS, IL-1RAP levels were greater than those in healthy controls. In a cohort of patients with AML, high IL-1RAP expression was associated with poor overall survival ($p=2.2 \times 10^{-7}$). Ongoing work includes investigating IL-1RAP as a prognostic marker in chronic myelogenous leukemia (CML) and as marker of leukemic stem cells.</p> <p>Anti-IL-1RAP, a mAb against IL-1RAP from Cantargia AB, is in preclinical development to treat melanoma.</p> <p>SciBX 5(27); doi:10.1038/scibx.2012.698 Published online July 12, 2012</p>	Patented by the Albert Einstein College of Medicine of Yeshiva University; available for licensing or partnering	<p>Barreyro, L. <i>et al. Blood</i>; published online June 21, 2012; doi:10.1182/blood-2012-01-404699 Contact: Ulrich Steidl, Albert Einstein College of Medicine of Yeshiva University, Bronx, N.Y. e-mail: ulrich.steidl@einstein.yu.edu</p>